Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
22 März 2023 - 12:04PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
22 March 2023 11:00 GMT
Notice of Annual General Meeting and Board Committee
change
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2023 and Shareholders’
Circular (the Notice).
The Company also announced that, in line with the UK
Corporate Governance Code, Michel Demaré will step down as a
member of the Audit Committee at the conclusion of this
year’s Annual General Meeting (AGM) following his appointment
as Chair of the Board.
The Notice and the proxy form for the AGM have been submitted to
the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website at
www.astrazeneca.com/noticeofmeeting2023.
The Company's Annual Report and Form 20-F Information 2022 (the
Annual Report) was published on 21 February 2023.
The Notice is being despatched to shareholders today.
The meeting place for the AGM will be the Leonardo Royal Hotel
London Tower Bridge, 45 Prescot Street, London, E1 8GP and the AGM
will commence at 2.30 pm (BST) on 27 April 2023.
The business to be conducted at the AGM is summarised
below:
1.
To
receive the Company’s Accounts, the Reports of the Directors
and Auditor and the Strategic Report for the year ended 31 December
2022
3.
To
reappoint PricewaterhouseCoopers LLP as Auditor
4.
To
authorise the Directors to agree the remuneration of the
Auditor
5.
To
elect or re-elect Directors
6.
To
approve the Annual Report on Remuneration for the year ended 31
December 2022
7.
To
authorise limited political donations
8.
To
authorise the Directors to allot shares
9.
To
authorise the Directors to disapply pre-emption rights
10.
To
authorise the Directors to further disapply pre-emption rights for
acquisitions and specified capital investments
11.
To
authorise the Company to purchase its own shares
12.
To
reduce the notice period for general meetings
13.
To
adopt new Articles of Association of the Company.
Pursuant to Regulation 41 of the Uncertificated
Securities Regulations 2001, only holders of ordinary shares
entered in the register of members of the Company by 6.30pm (BST)
on 25 April 2023 (or their duly appointed proxies), or if this
meeting is adjourned, in the register of members by 6.30pm (BST)
two days prior to any adjourned meeting, are entitled to attend or
vote at the AGM in respect of the number of ordinary shares
registered in their name at that time. Changes to the entries in
the register of members after 6.30pm (BST) on 25 April 2023, or if
this meeting is adjourned, in the register of members after 6.30pm
(BST) two days prior to any adjourned meeting, shall be disregarded
in determining the rights of any person to attend or vote at the
AGM. The
Record Date applied to the Euroclear Sweden system to determine
entitlement to attend and vote at the AGM is close of business on
18 April 2023.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For
details on how to contact the Investor Relations Team, please click
here. For Media
contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
22 March
2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Okt 2023 bis Okt 2024
